ML 03
Alternative Names: HP 3Latest Information Update: 08 Nov 2010
At a glance
- Originator Milkhaus Laboratory
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bronchitis; Chronic obstructive pulmonary disease; Cystic fibrosis; Respiratory tract disorders
Most Recent Events
- 26 Jul 2001 HP 3 is now called ML 03
- 26 Jul 2001 ML 03 is available for licensing (http://www.milkhaus.com/)
- 26 Jul 2001 Investigation in Respiratory tract disorders in USA (PO)